CCR5 and cancer: Chemokine receptor antagonist (CRA) drugs such as plerixafor (CXCR4 antagonist) or maraviroc (CCR5 antagonist) have been shown to induce suppression of cancer cell proliferation, migration, and metastasis [58,59].